C4 therapeutics announces fda orphan drug designation for cft7455 for the treatment of multiple myeloma

Watertown, mass., aug. 11, 2021 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the u.s. food and drug administration (fda) has granted orphan drug designation (odd) to cft7455 for the treatment of multiple myeloma.
CCCC Ratings Summary
CCCC Quant Ranking